Stryker (NYSE:SYK – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.450-13.700 for the period, compared to the consensus estimate of 13.510. The company issued revenue guidance of -.
Analyst Ratings Changes
Several research analysts have commented on the company. Truist Financial raised their price objective on Stryker from $380.00 to $409.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their price target on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, UBS Group raised their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $405.80.
Get Our Latest Analysis on Stryker
Stryker Trading Down 1.2 %
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. On average, sell-side analysts anticipate that Stryker will post 12.06 earnings per share for the current fiscal year.
Stryker Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.84 dividend. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s dividend payout ratio (DPR) is presently 36.01%.
Insider Transactions at Stryker
In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
- Five stocks we like better than Stryker
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Basic Materials Stocks Investing
- What Does the Future Hold for Eli Lilly?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.